BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35793046)

  • 1. Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.
    Al Dahmani KM; Almalki MH; Ekhzaimy A; Aziz F; Bashier A; Mahzari MM; Beshyah SA
    Pituitary; 2022 Aug; 25(4):658-666. PubMed ID: 35793046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
    Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
    Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
    Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma.
    Rudman Y; Duskin-Bitan H; Masri-Iraqi H; Akirov A; Shimon I
    Pituitary; 2022 Dec; 25(6):882-890. PubMed ID: 36036309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
    George LD; Nicolau N; Scanlon MF; Davies JS
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS.
    Hamidi O; Van Gompel J; Gruber L; Kittah NE; Donegan D; Philbrick KA; Koeller KK; Erickson D; Natt N; Nippoldt TB; Young WF; Bancos I
    Endocr Pract; 2019 Apr; 25(4):340-352. PubMed ID: 30995432
    [No Abstract]   [Full Text] [Related]  

  • 10. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.
    Shimon I; Benbassat C; Tzvetov G; Grozinsky-Glasberg S
    Pituitary; 2011 Mar; 14(1):11-5. PubMed ID: 20717729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal testosterone level to improve symptoms of hypogonadism without causing dopa-testotoxicosis in male macroprolactinoma.
    Telci Caklili O; Ok AM; Istemihan Z; Selcukbiricik O; Yarman S
    Ann Endocrinol (Paris); 2022 Feb; 83(1):9-15. PubMed ID: 34871603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
    Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
    Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant prolactinoma in Asian-Indians: A single-center experience from Western India.
    Kumar S; Memon SS; Lila AR; Sarathi V; Sehemby M; Karlekar M; Sankhe S; Thakkar H; Patil VA; Shah N; Bandgar T
    Ann Endocrinol (Paris); 2023 Dec; 84(6):711-718. PubMed ID: 37866429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?
    Rudman Y; Duskin-Bitan H; Manisterski Y; Pertzov B; Akirov A; Masri-Iraqi H; Shimon I
    Clin Endocrinol (Oxf); 2021 Oct; 95(4):606-617. PubMed ID: 34160838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current diagnosis and treatment of hyperprolactinemia].
    Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
    Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
    Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
    Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Male prolactinomas presenting with normal testosterone levels.
    Shimon I; Benbassat C
    Pituitary; 2014 Jun; 17(3):246-50. PubMed ID: 23756784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of macroprolactinomas.
    Képénékian L; Cebula H; Castinetti F; Graillon T; Brue T; Goichot B
    Ann Endocrinol (Paris); 2016 Dec; 77(6):641-648. PubMed ID: 27641080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.